Drug Approval | April 17, 2024
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Submission based on results from pivotal phase III trial showing all primary endpoints met
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Sen spent a decade with Biocon and held various key roles,
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The investment will catalyse various components of the IndiaAI Mission
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
We are achieving the target of developed India by making our young children healthy today
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Subscribe To Our Newsletter & Stay Updated
